Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Sellas Life Sciences Group Inc (SLS)

Sellas Life Sciences Group Inc (SLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Sellas Life Sciences Group Inc 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 USA

www.sellaslifesciences.com Employees: 16 P: 646-200-5278

Description:

SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present in an array of tumor types. SELLAS Life Sciences Group Inc., formerly known as Galena Biopharma Inc., is based in NEW YORK, United States.

Key Statistics

Overview:

Market Capitalization, $K 87,274
Enterprise Value, $K 84,644
Shares Outstanding, K 70,382
Annual Sales, $ 0 K
Annual Net Income, $ -37,340 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -7,110 K
EBIT, $ -32,780 K
EBITDA, $ -22,780 K
60-Month Beta 2.39
% of Insider Shareholders 1.20%
% of Institutional Shareholders 17.38%
Float, K 69,537
% Float 98.80%
Short Volume Ratio 0.30

Growth:

1-Year Return 25.77%
3-Year Return -82.67%
5-Year Return -73.48%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 99.19%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.10 on 11/13/24
Next Earnings Date 11/14/24
Earnings Per Share ttm -0.69
EPS Growth vs. Prev Qtr 23.08%
EPS Growth vs. Prev Year 69.70%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-50 on 11/08/19

SLS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -629.45%
Return-on-Assets % -178.65%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 5.22
Book Value/Share 0.25
Interest Coverage -1.69
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar